Business Description
Biohaven Ltd
NAICS : 541714
SIC : 2834
ISIN : VGG1110E1079
Total Employee Number:
274Description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.22 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 2.21 | |||||
Debt-to-EBITDA | -0.44 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.6 | |||||
3-Year EPS without NRI Growth Rate | 24.2 | |||||
3-Year FCF Growth Rate | 9.2 | |||||
3-Year Book Growth Rate | -63.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.23 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.71 | |||||
9-Day RSI | 49.18 | |||||
14-Day RSI | 53.31 | |||||
3-1 Month Momentum % | 25.42 | |||||
6-1 Month Momentum % | 7.02 | |||||
12-1 Month Momentum % | -3.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.41 | |||||
Quick Ratio | 7.41 | |||||
Cash Ratio | 6.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.9 | |||||
Shareholder Yield % | -19.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -579.84 | |||||
ROA % | -138.61 | |||||
ROIC % | -492.07 | |||||
3-Year ROIIC % | -729.57 | |||||
ROC (Joel Greenblatt) % | -1134.04 | |||||
ROCE % | -185.13 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 18.03 | |||||
Price-to-Tangible-Book | 21.25 | |||||
EV-to-EBIT | -3.48 | |||||
EV-to-EBITDA | -3.53 | |||||
EV-to-Forward-EBITDA | -4.77 | |||||
EV-to-Forward-Revenue | 20.79 | |||||
EV-to-FCF | -3.82 | |||||
| Price-to-Net-Current-Asset-Value | 48.47 | |||||
| Price-to-Net-Cash | 221.57 | |||||
Earnings Yield (Greenblatt) % | -28.74 | |||||
FCF Yield % | -25.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:BHVN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biohaven Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.67 | ||
| Beta | 1.0533 | ||
| 3-Year Sharpe Ratio | 0.05 | ||
| 3-Year Sortino Ratio | 0.07 | ||
| Volatility % | 69.73 | ||
| 14-Day RSI | 53.31 | ||
| 14-Day ATR ($) | 1.065211 | ||
| 20-Day SMA ($) | 15.399 | ||
| 12-1 Month Momentum % | -3.42 | ||
| 52-Week Range ($) | 7.48 - 18.5657 | ||
| Shares Outstanding (Mil) | 150.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biohaven Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biohaven Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 112 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 21 days | ||
| First quarter earnings results for 2026 | 2026-05-12 | 9.08 (-7.06%) | ||
| General meeting for 2026 | 2026-05-05 10:00 | 10.14 (+5.74%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 9.63 (-0.72%) | ||
| General meeting for 2026 | 2026-04-28 10:00 | 9.59 (-1.84%) | ||
| Annual report for 2025 | 2026-03-02 | 11.52 (+4.73%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-02 | 11.52 (+4.73%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-12 11:15 | 11.11 (-5.12%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 8.26 (-1.08%) |
Show
Entries
Biohaven Ltd Frequently Asked Questions
What is Biohaven Ltd(BHVN)'s stock price today?
The current price of BHVN is $15.51. The 52 week high of BHVN is $18.57 and 52 week low is $7.48.
When is next earnings date of Biohaven Ltd(BHVN)?
The next earnings date of Biohaven Ltd(BHVN) is 2026-08-11 Est..
Does Biohaven Ltd(BHVN) pay dividends? If so, how much?
Biohaven Ltd(BHVN) does not pay dividend.
Guru Commentaries on NYSE:BHVN
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers